share_log

Inhibikase Therapeutics To Present Data From Phase 1/1b Study Of IkT-148009 At The Movement Disorders Society Congress

Benzinga Real-time News ·  Sep 15, 2022 08:07

IkT-148009 was well-tolerated with high systemic exposure and persistent penetration into the central nervous system (CNS) in older and elderly healthy volunteers and Parkinson's patients

No clinically significant adverse events observed

Actively enrolling Phase 2a '201' clinical trial of IkT-148009 in patients with untreated Parkinson's disease

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment